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Introduction
Top-down proteomics consists in the analysis of intact proteins 
using liquid chromatography coupled to mass spectrometry 
(LC-MS), followed by their identification by tandem mass 
spectrometry (MS/MS). This informs on the protein composi-
tion of the analyzed sample, and their potential combinations 
of post-translational modifications, splicing events, and/or 
mutations. Intact protein mass spectrometry (MS) recently 
increased in throughput1 and became quantitative,2,3 thereby 
allowing the in-depth characterization of proteoforms4 in 
complex samples.5 Such development was associated with the 
establishment of a specific lexicon,6,7 dedicated databases 
(repository.topdownproteomics.org), and, needless to say, a 
panel of bioinformatics tools.8-11
Typically, top-down and intact protein MS analysis relies on 
the measurement of the deconvoluted molecular weights 
(MWs) of proteoforms after separation by liquid chromatogra-
phy (LC). This can be facilitated by the graphical representa-
tion of LC-MS three-dimensional (3D) maps, where the x-axis 
represents retention time (RT), the y-axis represents deconvo-
luted MW, and the color represents the intensity of the MS 
signal. In addition, directly comparing these maps reveals 
differences in proteoform footprints between samples and/or 
experimental conditions.1,8,12–16 Recently, we developed a free 
standalone tool to facilitate this analytical step: VisioProt-MS.17 
Here, we will illustrate its use through the analysis of the 20S 
core particle of the human proteasome.
The proteasome is a ubiquitous macromolecular barrel-
shaped complex of around 700 kDa that is responsible for pro-
tein degradation in eukaryotic cells.18 It is vital to maintain 
protein homeostasis and the pool of free amino acids available 
for protein synthesis. It also contributes to the immune response 
through production of antigenic peptides. Its catalytic activity 
resides in the 20S core particle that is composed of 4 rings of 7 
subunits each: two β-rings (β1-7) surrounded by two α-rings 
(α1-7). The names and theoretical MWs of these subunits are 
presented in Table 1. β1, β2, and β5 are the only subunits that 
are catalytically active in the standard 20S (std20S), and they 
can be replaced by β1i, β2i, and β5i to form the immunopro-
teasome (i20S) in the context of immune response. This leads 
to 2 different functional complexes that have distinct catalytic 
activities.19 The proteasome is highly studied in academia and 
industry in the context of drug development. The 20S core 
particle can be immunopurified using the anti-α2 antibody 
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MCP21,20,21 and as it is constituted of subunits of ~20 to ~30 
kDa, it is specifically suited for top-down and intact protein 
MS analysis.8 We present here the comparative top-down 
analysis of in-house-produced std20S and commercial samples 
of purified std20S and i20S using VisioProt-MS.
Material and Methods
Reagents
All reagents were provided by Sigma-Aldrich unless otherwise 
specified. Commercial standard and immuno-20S were pur-
chased from Enzo Life Science.
In-house purif ication of endogenous 20S
Endogenous 20S was purified from Hek293-EBNA cells 
grown to 80% confluency in Iscove’s Modified Dulbecco’s 
Medium (IMDM; Thermo Fisher) supplemented with 10% 
fetal bovine serum (FBS), 116 mg/mL L-Arginine, and 36 mg/
mL L-asparagine (Acros Organics) at 37°C and 5% CO2. Cells 
were then washed twice with phosphate-buffered saline (PBS) 
and stored at –80°C. On the day of experiment, 50 × 106 cells 
were lysed with 2 mL of lysis buffer (10 mM HEPES with pH 
7.9, 10 mM KCl, 5 mM MgCl2, 10% glycerol, 10 mM adeno-
sine triphosphate [ATP], 1% NP40, protease Complete and 
phosphatase PhosSTOP inhibitors from Roche), incubated for 
15 minutes at 4°C, and sonicated (Bioruptor Plus; Diagenode). 
Non-soluble debris were removed by centrifugation (4000g 
for 15 minutes at 4°C) and the protein concentration in the 
supernatant was determined by detergent-compatible (DC) 
assay (Bio-Rad). Aliquots were kept at –80°C until analysis. 
Immunopurification of the endogenous 20S core proteasome 
was performed as described in Fabre et al.21
Intact protein and top-down MS analysis
Nano-LC-MS and MS/MS analyses of commercial or 
immunopurified 20S were performed on a nanoRS UHPLC 
system (Dionex) coupled to an LTQ-Orbitrap Fusion Tribrid 
mass spectrometer (Thermo Fisher Scientific). A total of 
5 μL of sample at 0.3 µM was loaded onto a reverse-phase 
C4-precolumn (300 μm i.d. × 5 mm; Thermo Fisher 
Scientific) at 20 μL/min in 2% acetonitrile (ACN) and 0.2% 
formic acid (FA). After 5 minutes of desalting, the precolumn 
was switched online with an analytical C4 nanocolumn (75 
μm i.d. × 15 cm; in-house packed with C4 Reprosil) equili-
brated in 95% solvent A (5% ACN, 0.2% FA) and 5% solvent 
B (0.2% FA in ACN). Proteins were eluted using a binary gra-
dient ranging from 5% to 40% (5 minutes) and then 40% to 
99% (33 minutes) of solvent B at a flow rate of 300 nL/min. 
For the commercial 20S samples, the Fusion Tribrid (Thermo 
Fisher Scientific) was operated in single MS acquisition 
mode with the Xcalibur software (Thermo Fisher Scientific). 
The spray voltage was set to 1900 V, the ion transfer tube tem-
perature to 300°C, the RF lens to 60%, and the in-source dis-
sociation to 50 V. The MS scans were acquired in the 700 to 
2000 m/z range with the resolution set to 60 000 and using 10 
µscans for averaging. For the intact protein and top-down MS 
analysis of the immunopurified std20s, the spray voltage was 
set to 1350 V, the ion transfer tube temperature to 270°C, the 
RF lens to 60%, and the in-source dissociation to 50 V. The 
MS and MS/MS scans were acquired in the 400 to 2000 m/z 
range with a resolution of 120 000 and using 3 µscans for aver-
aging. Ions of interest were selected according to an inclusion 
list of 14 precursor masses (corresponding to the 20S subu-
nits) that were analysed by MS/MS with the option “DDA if 
parent mass list not found” unchecked. The isolation window 
was set to 5 Th with electron-transfer/higher-energy collision 
dissociation (EThcD) fragmentation (electron-transfer disso-
ciation [ETD]: 20 ms and higher-energy collision dissocia-
tion [HCD]: 25%).
Data analysis and visualization
For MS traces, raw files were automatically deconvoluted with 
the rolling window deconvolution software RoWinPro8 and 
the proteoform footprints were visualized with VisioProt-MS 
v2.0.17 Top-down raw data were analyzed with Proteome 
Discoverer v2.2 (Thermo Scientific) using the ProSight PD 
Top-Down Low/High node. Briefly, intact protein spectra 
were deconvoluted with ReSpect (precursor mass between 20 
000 and 30 000 Da and 100 ppm mass tolerance, charge state 
range between 15 and 35). Tandem mass spectrometry spectra 
were deconvoluted with Xtract (S/N threshold = 3, m/z range 
between 200 and 2000 Da, 60 000 resolution) and searched 
against a custom database including all human 20S subunits 
(generated in ProSight PC v4.0, Thermo Scientific). The 
search was performed in absolute mass mode with a fragment 
mass tolerance of 15 ppm and a precursor mass tolerance of 
200 Da. The MS/MS and proteoform-spectrum matches were 
visualized with VisioProt-MS. All the figures were adapted 
from VisioProt-MS exports using Adobe Illustrator CS6 
v16.0.0.
MS/MS Analysis of Immunopurified STD20s
We analyzed the endogenous 20S immunopurified from 
human Hek293T-EBNA cells22 using intact protein and top-
down MS. VisioProt-MS allowed the visualization of the 
most intense proteoforms based on their deconvoluted MWs 
(Figure 1A), and most of these were confirmed by MS/MS 
(Figure 1B). Besides the MS trace, the species selected for 
MS/MS during the top-down analysis are indicated by empty 
or filled circles for non-matched MS/MS and proteoform to 
spectrum matches, respectively. These can be dynamically 
explored with the “Show data labels” option in the sidebar 
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menu, which triggers dynamic labeling of the data points on 
hovering. Then, passing the mouse over them informs on the 
proteoform identified with each MS/MS and their RT, inten-
sity, and deconvoluted MW. It is also possible to highlight the 
MS/MS matched to specific proteoform(s) of interest such as 
β6 (PSMB1; Figure 1B, red points). The most intense proteo-
forms identified in this sample are presented in Table 1 (indi-
cated with the superscript “a”).
Beyond allowing an easy exploration of the identified pro-
teoforms, this representation allows the quick detection of false 
identifications. For example, in the box “b” (Figure 1B), some 
MS/MS have been matched to proteoforms in an empty area 
of the LC-MS map and are most probably background noise. 
In addition, the single red point overlaid to the β7 subunit MS 
trace corresponds to an MS/MS that was wrongly matched to 
β6 (Figure 1B). This could be due to an incorrect estimation of 
the precursor MW during deconvolution (potential wrong 
charge state assignment), or a wrong proteoform to spectral 
matching, and should not be taken into account for further 
analysis.
In addition to facilitating data curation, the MS/MS mode 
of VisioProt-MS can be used to optimize the acquisition and 
search parameters. The dashed rectangle “a” in Figure 1B high-
lights a proteoform that was not identified by MS/MS. We can 
see in this figure that several MS/MS were triggered on its 
elution, but none of them was matched to a protein sequence. 
This can be due to miss-adapted acquisition methods or search 
parameters that can be tuned to increase the number of proteo-
forms identified. In this sample, α7 is mostly phosphorylated, 
as reported in Gersch et al.8
Comparison of the std20S and i20S
To demonstrate the advantages of VisioProt-MS in the context 
of comparative sample analysis, we chose the commercial sam-
ples of std20S and i20S. Their LC-MS maps are presented in 
Figure 2, first alone with color-coded intensities (Figure 2A 
and B) and together for their direct comparison (Figure 2C). 
These graphical representations indicate the unexpected pres-
ence of the subunits β1, β2, and β5 among the i20S-specific 
subunits of the i20S sample, thereby highlighting a contamina-
tion by the std20S (Figure 2B).
Similar graphical representations can be used in other con-
texts beyond heterogeneous complex analysis, such as identifi-
cation of covalent drug binding,8 monitoring of protein 
maturation/processing, or identification of context-dependent 
post-translational modifications or protein variants.23-25 
Besides zooming and dynamic labeling of the data points, 
VisioProt-MS allows the user to hide experiment-dependent 
background noise with the “Threshold” option of the sidebar 
menu. This defines the percentage of high-intensity MS signal 
that is visualized on the LC-MS map. It is also possible to 
mask/unmask sample traces by clicking on their legends, which 
facilitates the exploration of overlapping signals such as the 
ones of β5 in Figure 2C.
Conclusions
For many years, the composition of the 20S core particle of the 
human proteasome was analyzed with methods such as low-
resolution two-dimensional (2D) sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) separation 
coupled with analytical techniques (Western blotting or 
Figure 1. Top-down analysis of immunopurified std20S: (A) 3D proteoform footprint of the LC-MS trace of 20S subunits generated with VisioProt-MS. The 
names of the std20S subunits are indicated next to the corresponding signal. (B) The same sample analyzed with MS/MS fragmentation for identification 
and visualized with the MS/MS mode of VisioProt-MS. The MS trace is color-coded with the «Red/yellow/blue» scale, and the MS/MS identified as β6 are 
indicated in red. Gray empty and filled circles are MS/MS that were not identified or proteoform-spectrum matches, respectively. The 2 rectangular 
selections (in red dashed lines) highlight (a) a non-identified proteoform (corresponding to the phosphorylated α7—based on its MW), and (b) potential 
false identifications (filled circles that do not overlap with a clear deconvoluted MS trace). Both figures were drawn with a VisioProt-MS «Threshold» 
parameter of 80%. LC-MS indicates liquid chromatography coupled to mass spectrometry; MS, mass spectrometry; MW, molecular weight.
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protein/peptide extraction followed by MS analysis).19,26 These 
methods prove the efficiency of 2D representations for map-
ping proteoforms of complex samples. However, such strategies 
are experimentally heavy, require a high amount of starting 
material, and rely on a priori knowledge on the different 
proteoforms present in the samples. Intact protein and top-
down MS remain limited in sensitivity and dynamic range. 
Furthermore, high-MW proteoforms are still very challenging 
to study with these techniques. Nevertheless, their ability to 
precisely measure proteoform MWs and fragment them in a 
system-wide setup already allows their application to the 
hypothesis-free exploration of complex samples.27 We believe 
that this could open the doors to personalized medicine at the 
proteoform level but would rely on technological progresses 
that go along with an increasing need for dedicated tools to 
facilitate data analysis.
VisioProt-MS is an easy solution to visualize and inspect 
intact protein and top-down MS data. It quickly provides an 
overview of all the detected MWs, reflecting data quality and 
reproducibility regarding observed MWs, intensities, and 
RTs. It allows comparison of not only multiple LC-MS 
runs (including from different deconvolution suites), but 
also LC-MS and LC-MS/MS runs of the same sample. 
Furthermore, its dynamic features enable to pinpoint potential 
Figure 2. Comparison of commercial std20S and i20S using intact protein MS: (A, B) MS trace of the subunits of the std20S (A, threshold: 35%) and i20s 
(B, threshold: 16%) visualized with VisioProt-MS in MS mode. The names of the identified subunits are indicated next to the corresponding signal. The 
subunits that are specific to the standard or immunoproteasome are indicated in blue and red, respectively. (C) overlay of the same samples for 
comparison of their proteoform composition (threshold: 35%). The MS trace is color-coded in function of the sample. A magnification of the area indicated 
with the dashed rectangular selection (“beta5 and beta5i”) is presented on the right. The names of the identified subunits are indicated next to the 
corresponding signal. The 3 beta5 traces correspond to the mature protein with 0, 1, or 2 oxidations. MS indicates mass spectrometry.
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new proteoforms, quickly reject wrongly assigned Proteoform 
Spectral Matches, and spot intense MS signals that remain 
unassigned.
Today, VisioProt-MS v2.0 is compatible with the following 
bioinformatics tools: RoWinPro,8 Intact Protein Analysis 
(BioPharma Finder 3.0, Thermo Fisher Scientific), 
DataAnalysis 4.2 (Bruker),9 TopFD (TopPIC Suite),10 and 
ProMex (Informed-Proteomics)11 for deconvoluted LC-MS 
data; and ProSight PD (Proteome Discoverer, Thermo), 
TopPIC (TopPIC Suite),10 and MSPathFinder (Informed-
Proteomics)11 for the LC-MS/MS data. It is open source and 
has been developed to be easily adaptable to other formats that 
may materialize from future technological development. 
Alternatively, it can be adapted and included in more complex 
workflows. All the information concerning its features, com-
patibility, and usages can be found in Locard-Paulet et al17 and 
on the associated online help (https://masstools.ipbs.fr/visio-
prothelp.html).
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